Recent Updates
Recently added Catalysts
PCVX Positive Sentiment

Vaxcyte to Present at the Jefferies Healthcare Conference

Key Takeaway: Vaxcyte, Inc. will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023. The company's focus is on creating innovative vaccines to combat bacterial diseases, including its lead candidate VAX-24. Vaxcyte utilizes advanced synthetic techniques for vaccine development, with a diverse pipeline targeting various bacterial infections. The event will feature a live webcast and a replay available for about 30 days post-conference.
Price reaction · baseline $49.52 (2023-05-31 close) · hit after-hours · clean, no other PCVX news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vaxcyte is participating in a prominent healthcare conference, signaling strong investor interest.
  • The company is developing innovative vaccines which could substantially impact public health.
  • Vaxcyte's advanced synthetic techniques for vaccine production showcase its commitment to innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
27.5%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
31 valent pneumococcal conjugate vaccine
Phase 3 · Pneumococcal Vaccines

Full Press Release Details

SAN CARLOS, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York on Thursday, June 8, 2023 at 10:30 a.m. ET / 7:30 a.m. PT.
A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Frequently Asked Questions

When is Vaxcyte's fireside chat at the Jefferies Healthcare Conference?

The chat will occur on June 8, 2023, at 10:30 a.m. ET.

How can I access the webcast of Vaxcyte's presentation?

The live webcast can be accessed on the Investors & Media section of Vaxcyte's website.

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead candidate is VAX-24, a 24-valent pneumococcal conjugate vaccine.

What technology does Vaxcyte use for vaccine production?

Vaxcyte utilizes the XpressCF™ cell-free protein synthesis platform for production.

What types of diseases does Vaxcyte's pipeline aim to address?

Vaxcyte's pipeline targets various bacterial infectious diseases, including Group A Strep.

Last updated: Jun 1, 2023